Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.06B P/E - EPS this Y -88.90% Ern Qtrly Grth -
Income -260.32M Forward P/E -3.24 EPS next Y 1.50% 50D Avg Chg 16.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -64.00%
Recommedations 3.50 Quick Ratio 18.43 Shares Outstanding 487.70M 52W Low Chg 37.00%
Insider Own 11.14% ROA -13.79% Shares Float 320.30M Beta 0.48
Inst Own 68.24% ROE -20.25% Shares Shorted/Prior 9.96M/13.37M Price 2.17
Gross Margin - Profit Margin - Avg. Volume 3,653,125 Target Price 2.10
Oper. Margin - Earnings Date - Volume 63,258,845 Change 7.43%
About EQRx, Inc.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.

EQRX Chatroom

User Image ChartMill Posted - 12/22/23

$EQRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry. https://www.chartmill.com/stock/quote/EQRX/fundamental-analysis?key=441b0b4f-77e9-4afc-838b-e3c2de5fc024&utm_source=HEALTH&utm_medium=stocktwits&utm_campaign=FA&utm_content=EQRX

User Image stockilluminati Posted - 11/20/23

$EQRX https://www.stockilluminati.com/eqrx/filings.php - EQRx, Inc. - Common Stock files form EFFECT today, check out the details.

User Image stockilluminati Posted - 5 months ago

$EQRX https://www.stockilluminati.com/eqrx/filings.php - EQRx, Inc. - Common Stock files form SC 13G/A today, check out the details.

User Image tickeron Posted - 5 months ago

This is amazing! What do you think? $EQRX The volume increased for one day, resulting in a record-breaking daily growth of 424% of the 65-Day Volume Moving Average. View odds of downtrend. https://srnk.us/go/4910481

User Image shortvolumes Posted - 5 months ago

2023-11-08 Short sale volume (not short interest) for $EQRX is 69%. http://shortvolumes.com/?t=EQRX via @shortvolumes

User Image Last10K Posted - 5 months ago

$EQRX just filed with the SEC a Change in Assets, a Listing Status, a Security Holders Change, a Change in Control, a Event for Officers, a Bylaw Change, a Vote of Security Holders and a Financial Exhibit https://last10k.com/sec-filings/EQRX/0001193125-23-274145.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=EQRX

User Image More_Rockets Posted - 5 months ago

$EQRX Merger details https://www.eqrx.com/news-releases/news-release-details/revolution-medicines-and-eqrx-stockholders-approve-eqrx

User Image tradethehalt Posted - 5 months ago

$EQRX trade halt (T12) was alerted to our Members at 7:50pm EST. Halt price: $2.39 Vol: 16.55M.

User Image Mergerbrief Posted - 5 months ago

$EQRX $RVMD - Shareholder Votes RVMD, EQRX MergerBrief.com

User Image J4CK_C4RT3R Posted - 5 months ago

$EQRX Delist on the 11/10/2023 (NASDAQ)

User Image Last10K Posted - 5 months ago

Last10K highlighted 31 positive and negative remarks in the $EQRX 10-Q filed today. See them in the Quarterly Report: https://last10k.com/sec-filings/EQRX/0001558370-23-017760.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=sentiment&utm_term=eqrx

User Image Last10K Posted - 5 months ago

$EQRX just filed a 10-Q Quarterly Report with 6 financial statements and 56 disclosures: https://last10k.com/sec-filings/eqrx/0001558370-23-017760.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=eqrx

User Image Greer1978 Posted - 5 months ago

$EQRX LYEL !!!!

User Image StockAutomatePro Posted - 5 months ago

$EQRX Looks like the stock may experience a strong rally chart confirms. We alerted the BUY signal at $2.06 and we were able to close this one with profit at $2.47 πŸ₯³

User Image StockAutomatePro Posted - 5 months ago

$EQRX The chart is pointing towards a potential boom in the stock. We alerted the BUY signal at $2.05 and we were able to close this one with profit at $2.34πŸ€™

User Image StockAutomatePro Posted - 5 months ago

$EQRX The chart is indicating a favorable market for the stock. We alerted the BUY signal at $2.06 and we were able to close this one with profit at $2.26πŸ€™

User Image ChartMill Posted - 10/26/23

$EQRX: Calling All EQRx, Inc. ($EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses https://www.chartmill.com/stock/quote/EQRX/news?utm_source=prnews-2023-10-26-calling-all-eqrx-inc-eqrx-investors-contact-bronstein-gewirtz-and-amp-grossman-llc-to-claim-your-losses&utm_medium=stocktwits&utm_campaign=pressRelease

User Image vu_jade Posted - 6 months ago

$EQRX great R&R

User Image StockAutomatePro Posted - 6 months ago

$EQRX Chart analysis confirms a potential uptrend for the stock. We alerted the BUY signal at $2.22 and we were able to close this one with profit at $2.39 🎲

User Image shortvolumes Posted - 6 months ago

2023-10-12 Short sale volume (not short interest) for $EQRX is 60%. http://shortvolumes.com/?t=EQRX via @shortvolumes

User Image stockilluminati Posted - 09/29/23

$EQRX https://www.stockilluminati.com/eqrx/filings.php - EQRx, Inc. - Common Stock files form DEFM14A today, check out the details.

User Image TeresaTrades Posted - 09/29/23

Largest CALL OI decreases $RIG $AZN $EQRX $META $AMZN http://staygreen.blackboxstocks.com/SH4GπŸŽ‰

User Image ChartMill Posted - 09/28/23

$EQRX has only a medium technical rating, but it does show a decent setup pattern. https://www.chartmill.com/stock/quote/EQRX/technical-analysis?key=441b0b4f-77e9-4afc-838b-e3c2de5fc024&utm_source=SETUP&utm_medium=stocktwits&utm_campaign=TA&utm_content=EQRX

User Image shortvolumes Posted - 09/22/23

The short sale volume (not short interest) for $EQRX on 2023-09-21 is 35%. http://shortvolumes.com/?t=EQRX via @shortvolumes

User Image nboyan Posted - 7 months ago

$EQRX

User Image tickeron Posted - 7 months ago

If you’re trading this week, Read This! $EQRX The volume increased for one day, resulting in a record-breaking daily growth of 417% of the 65-Day Volume Moving Average. View odds of downtrend. https://srnk.us/go/4857831

User Image nboyan Posted - 7 months ago

$EQRX

User Image kaefer Posted - 7 months ago

$GOVX $EQRX πŸ‘€ https://finance.yahoo.com/news/revolution-medicines-inc-acquire-eqrx-110000238.html

User Image ChartMill Posted - 08/31/23

Bull flags detected by our stock screener in $PLM, $EQRX and $CRGY. https://www.chartmill.com/stock/stock-screener?sid=13&f=v1_50b500,s_bf,exch_us&v=3&timeframe=DAILY&type=CANDLES&o1=3&op1=200,16711680&cl=F&months=0&o2=3&op2=50,255&width=400&o3=62&utm_source=Bull_Flags&utm_medium=stocktwits&utm_campaign=screen

User Image nboyan Posted - 08/29/23

$EQRX

Analyst Ratings
Goldman Sachs Neutral May 10, 23
JP Morgan Underweight Nov 14, 22
Goldman Sachs Neutral Nov 11, 22
Jefferies Hold Nov 11, 22
JP Morgan Neutral Aug 16, 22
Goldman Sachs Buy Jun 13, 22
Cowen & Co. Outperform Apr 22, 22
Jefferies Buy Mar 18, 22